C12N 2740/12011
Betaretrovirus
Official title: Betaretrovirus, e.g. mouse mammary tumour virus
C12N2740/12011 (Betaretrovirus) appears on 36 US grants and 40 published applications in this corpus.
Search patents in C12N- Granted patents
- 36
- Published applications
- 40
- Assignees
- 42
- Inventors
- 128
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 1 |
| 2005 | 1 | 0 |
| 2006 | 2 | 0 |
| 2007 | 0 | 4 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 5 |
| 2011 | 0 | 2 |
| 2012 | 1 | 1 |
| 2013 | 1 | 0 |
| 2014 | 1 | 2 |
| 2015 | 2 | 2 |
| 2016 | 1 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 2 |
| 2020 | 0 | 3 |
| 2021 | 1 | 2 |
| 2022 | 0 | 1 |
| 2023 | 1 | 1 |
| 2024 | 4 | 5 |
| 2025 | 2 | 4 |
| 2026 | 3 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2740/12022New viral proteins or individual genes, new structural or functional aspects ofIndexing code21
- C12N 2740/12041Use of virus, viral particle or viral elements as a vectorIndexing code10
- C12N 2740/12034Use of virus or viral component as vaccineIndexing code5
- C12N 2740/12023Virus like particles [vlp]Indexing code4
- C12N 2740/12061Methods of inactivation or attenuationIndexing code2
- C12N 2740/12021Viruses as suchIndexing code1
- C12N 2740/12031Uses of virus other than therapeutic or vaccineIndexing code0
- C12N 2740/12032Use of virus as therapeutic agent, other than vaccineIndexing code0
All 12 subgroupsShow fewer
Recent patents
- HERV-K (HML-2) Env analog fusion proteins for antigen specific immunotherapy and methods of use29 Sep 2026US 12,747,270 B2Twilight Bioscience, Inc.
- Recombinant retroviral vectors for gene therapy25 Aug 2026US 12,716,074 B1United Arab Emirates University
- HERV-K (HML-2) Env analog fusion proteins for antigen specific immunotherapy and methods of use4 Aug 2026US 12,698,309 B2Twilight Bioscience, Inc.
- VLP-based monovalent ebola vaccines and methods of making and using same30 Sep 2025US 12,427,190 B2Children's Hospital Medical Center
- VLP-based bivalent Ebola vaccines and methods of making and using same22 Apr 2025US 12,280,100 B2Children's Hospital Medical Center
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use5 Feb 2026US 2026/0035414 A1Twilight Bioscience, Inc.
- Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use5 Feb 2026US 2026/0035415 A1Twilight Bioscience, Inc.
- Glycoproteins for pseudotyping retroviral vector particles25 Dec 2025US 2025/0388924 A1Medizinische Hochschule Hannover
- Modular betaretrovirus receptor attachment and cell entry proteins8 May 2025US 2025/0144238 A1
Most cited
By later US patents
- Methods of enhancing antigen-specific T cell responses55US 5,738,852 ASolis Therapeutics, Inc. · 1998
- Engineered antigen presenting cells and methods for their use42US 5,962,320 ALeland Stanford Junior University · 1999
- Method for providing a cell culture from a transgenic non-human mammal30US 5,087,571 APresident and Fellows of Harvard College · 1992
- Retroviral superantigens, superantigen peptides, and methods of use9US 5,519,114 AUniversity of Florida Research Foundation, Inc. · 1996
- Testing method using transgenic mice expressing an oncogene8US 5,925,803 APresident and Fellows of Havard College · 1999